XCUR News and Press, Exicure Inc.

2024-06-17 16:09:49 ET More on Exicure Financial information for Exicure Read the full article on Seeking Alpha For further details see: Exicure GAAP EPS of -$0.10, revenue of $0.5M

Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspe...

2024-06-06 16:05:57 ET More on Exicure Financial information for Exicure Read the full article on Seeking Alpha For further details see: Exicure GAAP EPS of -$2.11

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activitie...

A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 121.3% to $0.3941 on volume of 248,629,940 shares Sharps Technology Inc. (STSS) rose 184.6% to $0.61 on volume of 114,390,080 shares Crown Electrokinetics Corp. (CRKN) rose 31.2% to $0.1325 on volume ...

2024-05-23 16:26:38 ET More on Exicure Financial information for Exicure Read the full article on Seeking Alpha For further details see: Exicure receives Nasdaq notice of a delisting determination

Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq ...

2024-05-16 16:41:38 ET More on Exicure Financial information for Exicure Read the full article on Seeking Alpha For further details see: Exicure GAAP EPS of -$0.61

Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activiti...

2024-04-22 16:20:28 ET More on Exicure Financial information for Exicure Read the full article on Seeking Alpha For further details see: Exicure received Nasdaq delinquency notice on late filing of Form 10-K